GRCE (Grace Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Grace Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Grace Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-4.12 Mil. Grace Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Grace Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Grace Therapeutics's current FCF Yield % is -39.48%.

The historical rank and industry rank for Grace Therapeutics's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Grace Therapeutics was -1388.89%. The lowest was -7340.82%. And the median was -4364.86%.

GRCE's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.23
* Ranked among companies with meaningful FCF Margin % only.

Grace Therapeutics FCF Margin % Historical Data

The historical data trend for Grace Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grace Therapeutics FCF Margin % Chart

Grace Therapeutics Annual Data

Trend

Feb14

Feb15

Feb16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

Get a 7-Day Free Trial

-7,340.82

Grace Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Grace Therapeutics's FCF Margin %

For the Biotechnology subindustry, Grace Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grace Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's FCF Margin % falls into.

Grace Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Grace Therapeutics's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	-12.355	/	0
	=	%

Grace Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-4.115	/	0
	=	%

Grace Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Grace Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Grace Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Grace Therapeutics Inc (NAS:GRCE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540

Website

https://www.acastipharma.com

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Executives

George Kottayil	director	49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren	director	282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru	director	11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds	director	545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar	officer: VP Program Management	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea	officer: VP Clinical Operations	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli	officer: Chief Executive Officer	206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald	officer: Chief Medical Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby	director	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine	director
Rajitha Grace 2018 Irrevocable Trust	10 percent owner	40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer	10 percent owner	20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford	officer: CHIEF FINANCIAL OFFICER	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan	director	C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202